Given that aberrant mTOR signaling is a well-established driver of tumor growth, EMT, metastasis, and resistance to cell death [63,64,65,66], targeting this pathway represents a compelling therapeutic strategy for preventing the progression of FA− deficient cancers. This evidence concerns the gene MTOR and neoplasm.